P2RY12 and pulmonary embolism: Our results may be that ticagrelor is a potent P2Y12 adenosine diphosphate platelet receptor inhibitor that decreases platelet activation in the acute phase of ischemic stroke, which prevents the release of neurotoxic and thrombogenic eicosanoids, including thromboxane B2, and, as a result, it might reduce early death and improve outcomes in survivors by reducing the volume of brain penumbra and reducing the risk of early recurrent ischemic stroke and pulmonary embolism Van Kotte and colleagues (1994) and Wallentin and colleagues (2009) [19, 20].